This is the authors' abstract. We don't add key points for this paper.
The highly conserved human leukocyte antigen-A2 (HLA-A2)-restricted epitope NS3-1073 represents a promising candidate for a therapeutic vaccine against hepatitis C virus (HCV). In this study, we engineered a set of fusion proteins based on the artificial peptide SAP, which were expressed in Escherichia coli and spontaneously self-assembled into nanosized particles displaying HCV epitopes, including NS3-1073. To enhance immunogenicity, the T helper epitope PADRE was incorporated into the construct. Alpha-helical linkers were introduced between SAP and the epitopes to facilitate proper protein folding. Notably, a helical linker with a high supercoiling propensity enabled soluble expression of the fusion protein containing both the NS3-1073 and PADRE, allowing purification of the in vivo-formed nanoparticles by metal affinity chromatography. Human dendritic cells derived from peripheral blood monocytes showed robust activation in response to the fusion proteins and preferentially stimulated T lymphocytes toward a Th1-biased immune response. In mice, immunization with nanoparticles carrying NS3-1073 induced splenocyte proliferation in response to in vitro stimulation with a mixture of NS3 peptides. These results demonstrate that recombinant nanoparticle-based carriers presenting the NS3-1073 epitope can be produced in bacterial systems and hold strong potential as a foundation for a therapeutic HCV vaccine.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kuprianov et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: